More IVD Mergers: Agilent Buys Resolution, Hologic Acquires Diagenode
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.
You may also be interested in...
Mobidiag develops molecular diagnostic tests and instrumentation that will expand Hologic’s acute care testing capabilities.
Plus deals involving AbbVie/Mitokinin, Roivant/Silicon Therapeutics, CASI/Cleave Therapeutics, Tallac/ALX Oncology, AgeX/LyGenesis, Chinook/Evotec and more.
Lucid, which markets the EsoGuard test for Barrett’s esophagus, will become a separate public company, either through an IPO or a business combination with a health care SPAC.